Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

NCT01275248 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

130

Enrollment

INDUSTRY

Sponsor class

Stopped lack of efficacy

Conditions

Obsessive-compulsive Disorder

Interventions

DRUG: Ondansetron
DRUG: Placebo

Sponsor

Transcept Pharmaceuticals